Stocktoria
SCYNEXIS INC SCYX
SCYNEXIS INC (SCYX) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $20.6M at a -41.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.587 |
| Retained earnings / assets | -6.525 |
| EBIT / assets | -0.272 |
| Equity / liabilities | 5.116 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SCYX | SCYNEXIS INC | 4/9 | -13.88 | — | — |
| SLGL | Sol-Gel Technologies Ltd. | 5/9 | -19.59 | — | +68% |
| NAMS | NewAmsterdam Pharma Co N.V. | 2/9 | 8.19 | — | -50.6% |
| ALMS | ALUMIS INC. | 1/9 | -7.78 | — | — |
| ZYBT | Zhengye Biotechnology Holding Ltd | 4/9 | 1.49 | — | -91.1% |
| QURE | uniQure N.V. | 4/9 | -1.71 | — | -40.6% |
| TRDA | Entrada Therapeutics, Inc. | 2/9 | 4.24 | — | -87.9% |
About SCYNEXIS INC
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
FAQ
Is SCYX financially healthy?
SCYNEXIS INC's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does SCYX pay a dividend?
No, SCYNEXIS INC does not currently pay a dividend.
How profitable is SCYX?
In FY2025, SCYNEXIS INC had a net margin of -41.8% and a return on equity of -17.4%.
What is the analyst price target for SCYX?
The average Wall-Street price target for SCYNEXIS INC is $33.55, about 597.4% above the recent price, from 3 analysts.
Is SCYX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on SCYNEXIS INC: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.